文献速递艾滋病与性传播感染

中断/延迟抗逆转录病毒治疗对疾病风险的影响:SMART与START联合分析

The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis.
PubMed 文献 · J Infect Dis · 2019-01-01

该分析 pooled SMART 与 START 两项试验数据,比较延迟/间歇与立即/持续抗逆转录病毒治疗(ART)对艾滋病、严重非艾滋病事件、心血管疾病、癌症及死亡风险的影响。共纳入 10156 名参与者,延迟/间歇 ART 组上述终点风险均高于立即/持续 ART 组,两试验治疗组间 CD4 计数和病毒抑制差异相似,相对风险差异也相似,但因 SMART 基线风险更高,其绝对风险差异更大。

要点

  • 延迟/间歇 ART 相比立即/持续 ART,艾滋病风险 HR 3.63(95%CI 2.37-5.56)。
  • 严重非艾滋病事件 HR 1.62(1.25-2.09),心血管疾病 HR 1.59(1.07-2.37)。
  • 癌症 HR 1.93(1.32-2.83),死亡 HR 1.80(1.24-2.61)。

核心结论

  • SMART 与 START 两试验中治疗组间 CD4 计数和病毒抑制差异相似,延迟/间歇与立即/持续 ART 之间艾滋病和严重非艾滋病事件的相对风险差异也相似。

研究设计与样本

  • 联合分析 SMART 和 START 两项试验的 pooled 数据,比较延迟/间歇与立即/持续 ART 对疾病风险的影响。
  • 共纳入 10156 名参与者。

主要发现

  • 共发生 124 例艾滋病、247 例严重非艾滋病事件、117 例癌症、103 例心血管疾病和 120 例死亡。
  • 延迟/间歇 ART 对比立即/持续 ART 的 pooled HR(95%CI):艾滋病 3.63(2.37-5.56);严重非艾滋病事件 1.62(1.25-2.09);心血管疾病 1.59(1.07-2.37);癌症 1.93(1.32-2.83);死亡 1.80(1.24-2.61)。
  • SMART 试验的基线潜在风险高于 START 试验,因两试验 HR 相似,治疗组间绝对风险差异在 SMART 中大于 START。
  • 各基线定义亚组间 pooled HR 相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pooled data from the SMART and START trials were used to compare deferred/intermittent versus immediate/continuous antiretroviral therapy (ART) on disease risk. METHODS: Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular disease (CVD), cancer, and death. Pooled (stratified by study) hazard ratios (HRs) from Cox models were obtained for deferred/intermittent ART versus immediate/continuous ART; analyses were conducted to assess consistency of HRs across baseline-defined subgroups. RESULTS: Among 10156 participants, there were 124 AIDS, 247 SNA, 117 cancers, 103 CVD, and 120 deaths. Interventions in each trial led to similar differences in CD4 count and viral suppression. Pooled HRs (95% confidence interval) of deferred/intermittent ART versus immediate/continuous ART were for AIDS 3.63 (2.37-5.56); SNA 1.62 (1.25-2.09); CVD 1.59 (1.07-2.37); cancer 1.93 (1.32-2.83); and death 1.80 (1.24-2.61). Underlying risk was greater in SMART than START. Given the similar HRs for each trial, absolute risk differences between treatment groups were greater in SMART than START. Pooled HRs were similar across subgroups. CONCLUSIONS: Treatment group differences in CD4 count and viral suppression were similar in SMART and START. Likely as a consequence, relative differences in risk of AIDS and SNA between immediate/continuous ART and deferred/intermittent ART were similar. CLINICAL TRIALS REGISTRATION: NCT00027352 and NCT00867048.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Borges ÁH, Neuhaus J, Sharma S, et al. The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. J Infect Dis. 2019. PMID: 30032171. doi:10.1093/infdis/jiy442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。